company background image
IMC

ImmuronASX:IMC Stock Report

Market Cap

AU$25.0m

7D

-8.3%

1Y

-53.2%

Updated

03 Dec, 2021

Data

Company Financials
IMC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMC Stock Overview

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Immuron
Historical stock prices
Current Share PriceAU$0.11
52 Week HighAU$0.28
52 Week LowAU$0.11
Beta1.91
1 Month Change-15.38%
3 Month Changen/a
1 Year Change-53.19%
3 Year Change-56.86%
5 Year Change-61.40%
Change since IPO-98.90%

Recent News & Updates

Oct 01
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Mar 30
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, Immuron ( ASX:IMC...

Shareholder Returns

IMCAU BiotechsAU Market
7D-8.3%-2.2%-0.7%
1Y-53.2%4.4%9.8%

Return vs Industry: IMC underperformed the Australian Biotechs industry which returned 4.4% over the past year.

Return vs Market: IMC underperformed the Australian Market which returned 9.8% over the past year.

Price Volatility

Is IMC's price volatile compared to industry and market?
IMC volatility
IMC Average Weekly Movement11.4%
Biotechs Industry Average Movement8.5%
Market Average Movement8.3%
10% most volatile stocks in AU Market15.7%
10% least volatile stocks in AU Market3.7%

Stable Share Price: IMC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IMC's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994n/aJerry Kanelloshttps://www.immuron.com.au

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver.

Immuron Fundamentals Summary

How do Immuron's earnings and revenue compare to its market cap?
IMC fundamental statistics
Market CapAU$25.03m
Earnings (TTM)-AU$8.38m
Revenue (TTM)AU$145.78k

171.9x

P/S Ratio

-3.0x

P/E Ratio

Valuation

Is Immuron undervalued compared to its fair value and its price relative to the market?

0.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMC is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: IMC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMC is good value based on its PB Ratio (1x) compared to the AU Biotechs industry average (5x).


Future Growth

How is Immuron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immuron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Immuron performed over the past 5 years?

1.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMC is currently unprofitable.

Growing Profit Margin: IMC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMC is unprofitable, but has reduced losses over the past 5 years at a rate of 1.1% per year.

Accelerating Growth: Unable to compare IMC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).


Return on Equity

High ROE: IMC has a negative Return on Equity (-32.38%), as it is currently unprofitable.


Financial Health

How is Immuron's financial position?


Financial Position Analysis

Short Term Liabilities: IMC's short term assets (A$25.8M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: IMC's short term assets (A$25.8M) exceed its long term liabilities (A$36.2K).


Debt to Equity History and Analysis

Debt Level: IMC is debt free.

Reducing Debt: IMC has no debt compared to 5 years ago when its debt to equity ratio was 38.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IMC has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 8.9% each year


Dividend

What is Immuron current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.9yrs

Average board tenure


CEO

Jerry Kanellos (60 yo)

1.75yrs

Tenure

AU$372,523

Compensation

Dr. Jerry Kanellos, Ph D has been Chief Executive Officer of Immuron Limited since March 25, 2020 and is its Chief Operating Officer since July 28, 2015. Dr. Kanellos served as Interim Chief Executive Offi...


CEO Compensation Analysis

Compensation vs Market: Jerry's total compensation ($USD264.61K) is about average for companies of similar size in the Australian market ($USD291.30K).

Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.


Board Members

Experienced Board: IMC's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Immuron Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Immuron Limited
  • Ticker: IMC
  • Exchange: ASX
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$25.034m
  • Shares outstanding: 227.58m
  • Website: https://www.immuron.com.au

Location

  • Immuron Limited
  • 25-37 Chapman Street
  • Unit 10
  • Carlton
  • Victoria
  • 3130
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/03 15:57
End of Day Share Price2021/12/03 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.